Enclomiphene is a non-steroidal selective estrogen receptor modulator (SERM) that is being investigated for its potential use in treating secondary hypogonadism in men. It is an isomer of clomiphene citrate, a drug that has been used for decades to induce ovulation in women. While clomiphene citrate is a mixture of two isomers, enclomiphene and zuclomiphene, enclomiphene is thought to be the primary therapeutically active component responsible for stimulating gonadotropin release. In men, secondary hypogonadism is characterized by low testosterone levels due to impaired testicular function resulting from abnormal pituitary or hypothalamic signaling. Enclomiphene aims to address this by modulating estrogen receptors, ultimately leading to increased endogenous testosterone production.
Unlike traditional testosterone replacement therapy (TRT), which introduces exogenous testosterone and can suppress natural production, enclomiphene works by stimulating the body's own hormone-producing mechanisms. This distinction is significant for men who wish to maintain their own testicular function and fertility. Enclomiphene is typically administered orally.
Deep dive
Tap a section to expand.
Known interactions
Category rule: peptide × hormone
Note
Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.
Track bloodwork with a provider; don't assume combinations are neutral.
Frequently asked
Sources referenced
["PubChem (National Library of Medicine)", "DrugBank", "FDA label (for related compounds/investigational summaries)", "Clinical trial literature (peer-reviewed scientific journals)"]
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the hormone category or studied for the same goals.